TORONTO, ONTARIO–(Marketwired – May 29, 2014) – Arch Biopartners Inc (Arch) or (the Company) (CSE:ACH)(OTCBB:FOIFF) announced today it has hired d3 Medicine to work as the Company’s new drug development team.
d3’s first task will be to design a Phase I/II human trial for MetaMx, the Company’s brain tumour targeting technology, in patients with malignant glioma.
TORONTO, ONTARIO–(Marketwired – April 17, 2014) – Arch Biopartners Inc (“Arch” or the “Company”) (CNSX:ACH)(OTCBB:FOIFF) announced today the board has appointed Claude Allary as an interim director.
Mr.
TORONTO, ONTARIO–(Marketwired – March 28, 2014) – Arch Biopartners Inc (Arch) or (the Company) (CSE:ACH)(OTCBB:FOIFF) announced today it has entered into a one year option agreement with the University of Cincinnati (UC) to exclusively license the commercial rights to a U.S.
TORONTO, ONTARIO–(Marketwired – March 12, 2014) – With profound sadness, Arch Biopartners Inc. announces the passing of its Chairman, Jerry McElroy. The Board and management will miss his friendship, guidance and good judgment since the formation of the company.
TORONTO, ONTARIO–(Marketwired – Feb. 25, 2014) – Arch Biopartners Inc (“Arch” or the “Company”) (CSE:ACH)(OTCBB:FOIFF) announced today it has raised $228,900 via a non-brokered private placement of 817,500 Units at a price of $0.28 per Unit.
TORONTO, ONTARIO–(Marketwired – Nov. 20, 2013) – Arch Biopartners Inc (Arch) or (the Company) (CNSX:ACH)(OTCBB:FOIFF) announced today that data relating to proprietary technology identifying brain tumor targeting peptides developed by Dr. Stephen Robbins, Dr.
TORONTO, ONARIO–(Marketwired – Sept. 17, 2013) – Arch Biopartners Inc (Arch) or (the Company) (CNSX:ACH)(OTCBB:FOIFF) announced today Dr. Patrick Smith and Dr. Craig Rayner of d3 Medicine have been appointed drug development advisors to the Company.
TORONTO, ONTARIO–(Marketwired – Sept. 12, 2013) – Arch Biopartners Inc (Arch) or (the Company) (CNSX:ACH)(OTCBB:FOIFF) announced today that the U.S. Patent and Trademark Office has issued US Patent 8,530,429 protecting its peptide technology which targets brain tumour initiating cells (BTICs) and invasive glioma cells (IGCs).
TORONTO, ONTARIO–(Marketwired – Aug. 14, 2013) – Arch Biopartners Inc (Arch) or (the Company)(CNSX:ACH) (OTCBB:FOIFF) announced today it has been accepted by the Consulate General of Canada, San Francisco/Silicon Valley to join the Life Sciences Canadian Technology Accelerator (CTA) at QB3 at the University of California San Francisco.
TORONTO, ONTARIO–(Marketwired – June 6, 2013) – Arch Biopartners Inc (Arch) or (the Company) (CNSX:ACH) (OTCBB:FOIFF) announced today that the U.S. Patent and Trademark Office has issued an additional patent for an invention preventing or inhibiting the growth of biofilm formation on surfaces.